BIOMARIN PHAR. DL-,001 | 72.16 / +1.18% |
Date/Time | 01/22 / 19:30 |
Chg. / Chg.(%) | 0.84 / +1.18% |
Bid | - |
Ask | - |
Open | 70.92 |
Previous Close | 71.32 |
High | 72.16 |
Low | 70.66 |
Volume [EUR] | 0.00 |
Volume [Units] | 0 |
Price fixings | 21 |
ISIN | US09061G1013 |
Security | BM8 |
Exchange | Düsseldorf |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Lang & Schwa.. | 71.73 | ![]() |
|
NASDAQ | 87.9900 | ![]() |
898,579 |
IEX | 88.01 | ![]() |
47,244 |
Cboe US | 88.15 | ![]() |
28,240 |
Mexico | 1,760.00 | ![]() |
662 |
Vienna Globa.. | 72.06 | ![]() |
248 |
TradeGate | 72.790 | ![]() |
149 |
London Inter.. | 86.80 | ![]() |
127 |
Frankfurt | 70.7600 | ![]() |
17 |
Stuttgart | 71.990 | ![]() |
10 |
Xetra | 72.11 | ![]() |
0 |
Berlin | 71.02 | ![]() |
0 |
München | 71.22 | ![]() |
0 |
Düsseldorf | 72.16 | ![]() |
0 |
gettex | 72.370 | ![]() |
News
- BioMarin sinks 32% as FDA delays its hemophilia treatment
08/19/2020 / 16:23 - TeleTrader - Nasdaq turns red as pharma stocks fall
04/28/2020 / 16:48 - TeleTrader - BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12/12/2016 / 14:29 - GlobeNewswire - NICE Recommends BioMarin's Vimizim® (elosulfase alfa) for the Treatment of Morquio A Syndrome in England
11/23/2015 / 16:59 - GlobeNewswire